reports
Ipsen announces that Beech Tree has obtained an exemption from the obl...
Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer PARIS, FRANCE, 3 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) announces that Beech Tree — which directly and indirectly holds 26.03% of Ipsen S.A.’s share capital and 33.05% of its voting rights — has obtained from the French Financial Markets Authority (Autorité des marchés financiers) an exemption from the obligation to file a public tender offer for all Ipsen S.A. shares.1 This decision is part of the transfer of Mr. Henri Beaufour’s stake in Beech Tree to the Alasol Foundatio...
Ipsen annonce l’obtention par Beech Tree d’une dérogation à l’obligati...
Ipsen annonce l’obtention par Beech Tree d’une dérogation à l’obligation de déposer une offre publique PARIS, FRANCE, 3 AVRIL 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce que Beech Tree - qui détient directement et indirectement 26,03 % du capital et 33,05 % des droits de vote d'Ipsen S.A. - a obtenu de l’Autorité des marchés financiers une dérogation la dispensant de déposer un projet d'offre publique visant l'intégralité des actions Ipsen S.A1. Cette décision s’inscrit dans le cadre du transfert de la participation de Monsieur Henri Beaufour dans Beech Tree au profit de la Fondation A...
- Ahmed Ben Salem
- Thomas Zlowodzki
AC ACCOR SA
HEIA HEINEKEN NV
IPN IPSEN SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
BVI BUREAU VERITAS SA
KNEBV KONE OYJ CLASS B
SAND SANDVIK AB
EL ESSILORLUXOTTICA SA
ITRK INTERTEK GROUP PLC
ZAL ZALANDO SE
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
01913 PRADA S.P.A.
REP REPSOL SA
ARCAD ARCADIS NV
RAA RATIONAL AG
MOCORP METSO OUTOTEC OYJ
EVK EVONIK INDUSTRIES AG
CFR COMPAGNIE FINANCIERE RICHEMONT SA
SIE SIEMENS AG
BP. BP P.L.C.
SIK SIKA AG
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
EPI A EPIROC AB
SHEL SHELL PLC
SGSN SGS SA
- Ahmed Ben Salem
- Thomas Zlowodzki
AC ACCOR SA
HEIA HEINEKEN NV
IPN IPSEN SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
BVI BUREAU VERITAS SA
KNEBV KONE OYJ CLASS B
SAND SANDVIK AB
EL ESSILORLUXOTTICA SA
ITRK INTERTEK GROUP PLC
ZAL ZALANDO SE
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
01913 PRADA S.P.A.
REP REPSOL SA
ARCAD ARCADIS NV
RAA RATIONAL AG
MOCORP METSO OUTOTEC OYJ
EVK EVONIK INDUSTRIES AG
CFR COMPAGNIE FINANCIERE RICHEMONT SA
SIE SIEMENS AG
BP. BP P.L.C.
SIK SIKA AG
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
EPI A EPIROC AB
SHEL SHELL PLC
SGSN SGS SA
- Christophe-Raphaël Ganet
- Christophe-Raphaël Ganet
Ipsen announces the availability of its 2025 Universal Registration Do...
Ipsen announces the availability of its 2025 Universal Registration Document Ipsen announces the availability of its 2025 Universal Registration Document PARIS, FRANCE, 1 APRIL 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced that its 2025 Universal Registration Document has been filed today with the French Autorité des Marchés Financiers (AMF) and registered under the number D.26-0202. The document is available on and . Copies will also be available at Ipsen’s headquarters – 70 rue Balard, 75015 Paris, France. The Universal Registration Document includes in particular: the Annual F...
Ipsen annonce la mise à disposition de son Document d’enregistrement u...
Ipsen annonce la mise à disposition de son Document d’enregistrement universel 2025 Ipsen annonce la mise à disposition de son Document d’enregistrement universel 2025 PARIS, FRANCE, 1er AVRIL 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY) annonce que son Document d’enregistrement universel 2025 a été déposé ce jour auprès de l’Autorité des Marchés Financiers (AMF) et enregistré sous le numéro D.26-0202. Ce document peut être consulté sur le site internet de la société à l’adresse et sur le site de l’AMF . Il sera également tenu à disposition au siège social de la Société – 70 rue Balard, 7...
- Amira Manai
- Andreas Riemann
A1XEH4 CROSSJECT SA
SBS STRATEC SE
LXS LANXESS AG
HCO HIGHCO SA
IPH INNATE PHARMA SA CLASS A
NTG NETGEM SA
NRG NRJ GROUP SA
LNA LNA SANTE SA
TRI TRIGANO SA
QDT QUADIENT SA
POS PORR AG
FFP FFP
DEZ DEUTZ AG
WIE WIENERBERGER AG
AALB AALBERTS N.V.
FACC FACC AG
SANT S&T AG
RBO ROCHE BOBOIS INTERNATIONAL SAS
JEN JENOPTIK AG
CLA CLARANOVA SE
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
MRX MISTER SPEX SE
ARVEN ARVERNE GROUP SA
- Amira Manai
- Andreas Riemann
A1XEH4 CROSSJECT SA
SBS STRATEC SE
LXS LANXESS AG
HCO HIGHCO SA
IPH INNATE PHARMA SA CLASS A
NTG NETGEM SA
NRG NRJ GROUP SA
LNA LNA SANTE SA
TRI TRIGANO SA
QDT QUADIENT SA
POS PORR AG
FFP FFP
DEZ DEUTZ AG
WIE WIENERBERGER AG
AALB AALBERTS N.V.
FACC FACC AG
SANT S&T AG
RBO ROCHE BOBOIS INTERNATIONAL SAS
JEN JENOPTIK AG
CLA CLARANOVA SE
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
MRX MISTER SPEX SE
ARVEN ARVERNE GROUP SA
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
- Dominic Rose
- Naresh Chouhan
Ipsen showcases transformative potential of early immuno-oncology pipe...
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s investigational antibody drug conjugate IPN60300, over-expressed across numerous solid tumor typesPreclinical data show potential of Ipsen’s growing collection of investigational medicines, leveraging precision immuno‑modulation to deliver differentiated anti‑tumor activity PARIS, FRANCE, 18 ...
Ipsen présente le potentiel transformateur de son pipeline d’immuno on...
Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR Les données précliniques d’IPN01203 seront dévoilées lors de la convoitée session « New Drugs on the Horizon », mettant en lumière le potentiel précoce de ce nouvel activateur de cellules T à transformer la prise en charge des tumeurs solides.ITGA2 identifié comme nouvelle cible de l’anticorps-conjugué (ADC) innovant IPN60300 d’Ipsen, fortement surexprimée dans de nombreux types de tumeurs solides.Ces données précliniques illustrent le potentiel croissant du portefeuille de médicaments expé...
Ipsen - February 2026 - Monthly information relative to the total numb...
Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)28 February 2026 83,814,526 Gross total* of ...
Ipsen - Février 2026 - Information mensuelle relative au nombre total ...
Ipsen - Février 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Paris Code ISIN : FR 0010259150LEI : 549300M6SGDPB4Z94P11 Date Nombre total d’actions composant le capital social Nombre total de droits de vote (1) 28 février 2...
Ipsen appoints Michelle C. Werner as EVP, President of North America
Ipsen appoints Michelle C. Werner as EVP, President of North America PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership Team (ELT) and will report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “I am very pleased to welcome Michelle to Ipsen and to the Executive Leadership Team. She brings a wealth of experience in leading teams both in the U.S. and around the world and has...
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follic...
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of seco...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.